Literature DB >> 22990138

Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru.

S S Shin1, L Asencios, M Yagui, G Yale, C Suárez, J Bayona, C Bonilla, O Jave, C C Contreras, S Atwood, J A Blaya, J Ershova, J P Cegielski.   

Abstract

SETTING: Programmatic implementation of decentralized rapid drug susceptibility testing (DST) in Lima, Peru.
OBJECTIVE: Pre-post analysis compared time to diagnosis, treatment outcome and survival among patients tested with direct nitrate reductase assay (NRA) vs. indirect conventional methods.
DESIGN: From 2005 to 2009, we prospectively followed all patients referred for DST before (control) and after (intervention) NRA implementation. Among those referred for DST, NRA was used for smear-positive samples of patients with no prior history of multidrug resistance or treatment for multidrug-resistant tuberculosis (TB). Data were abstracted from patient charts and laboratory registers. Endpoints were favorable outcomes, time to result and time to death.
RESULTS: Of those patients who met the criteria for NRA, 740 underwent NRA and 621 underwent conventional DST. NRA yielded test results for 78.4% of cases vs. 68.8% for conventional DST (P < 0.0001); the median time to result was 44 vs. 133 days, respectively (adjusted HR 0.64, 95%CI 0.56-0.73). Among individuals without previous anti-tuberculosis treatment, NRA was associated with a favorable treatment outcome (adjusted OR 1.39, 95%CI 1.01-1.90) and prolonged survival (adjusted HR 0.53, 95%CI 0.31-0.90).
CONCLUSION: Direct NRA significantly shortened time to test result and improved treatment outcomes and survival in certain groups.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22990138      PMCID: PMC5788451          DOI: 10.5588/ijtld.12.0071

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  21 in total

1.  Multicenter evaluation of the nitrate reductase assay for drug resistance detection of Mycobacterium tuberculosis.

Authors:  Anandi Martin; Ernesto Montoro; Dihadenys Lemus; Norberto Simboli; Nora Morcillo; Maritza Velasco; José Chauca; Lucía Barrera; Viviana Ritacco; Françoise Portaels; Juan Carlos Palomino
Journal:  J Microbiol Methods       Date:  2005-11       Impact factor: 2.363

2.  Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.

Authors:  K F Laserson; L E Thorpe; V Leimane; K Weyer; C D Mitnick; V Riekstina; E Zarovska; M L Rich; H S F Fraser; E Alarcón; J P Cegielski; M Grzemska; R Gupta; M Espinal
Journal:  Int J Tuberc Lung Dis       Date:  2005-06       Impact factor: 2.373

3.  Development, implementation and preliminary study of a PDA-based tuberculosis result collection system.

Authors:  Joaquin Blaya; Hamish S F Fraser
Journal:  AMIA Annu Symp Proc       Date:  2006

Review 4.  Clinical mycobacteriology. Drug susceptibility testing.

Authors:  L B Heifets
Journal:  Clin Lab Med       Date:  1996-09       Impact factor: 1.935

5.  Drug susceptibility testing of Mycobacterium tuberculosis by a nitrate reductase assay applied directly on microscopy-positive sputum samples.

Authors:  Humberto R Musa; Marta Ambroggi; Alejandro Souto; K A Kristian Angeby
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

6.  Validation of a rapid method for detection of M. tuberculosis resistance to isoniazid and rifampin in Lima, Peru.

Authors:  L A Solis; S S Shin; L L Han; F Llanos; M Stowell; A Sloutsky
Journal:  Int J Tuberc Lung Dis       Date:  2005-07       Impact factor: 2.373

7.  Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

Authors:  Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

8.  Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008.

Authors:  Gustavo E Velásquez; Martin Yagui; J Peter Cegielski; Luis Asencios; Jaime Bayona; Cesar Bonilla; Hector O Jave; Gloria Yale; Carmen Suárez; Sidney Atwood; Carmen C Contreras; Sonya S Shin
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

9.  Scale-up of multidrug-resistant tuberculosis laboratory services, Peru.

Authors:  Sonya S Shin; Martin Yagui; Luis Ascencios; Gloria Yale; Carmen Suarez; Neyda Quispe; Cesar Bonilla; Joaquin Blaya; Allison Taylor; Carmen Contreras; Peter Cegielski
Journal:  Emerg Infect Dis       Date:  2008-05       Impact factor: 6.883

10.  A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics.

Authors:  Joaquin A Blaya; Sonya S Shin; Martin J A Yagui; Gloria Yale; Carmen Z Suarez; Luis L Asencios; J Peter Cegielski; Hamish S F Fraser
Journal:  BMC Med Inform Decis Mak       Date:  2007-10-28       Impact factor: 2.796

View more
  5 in total

1.  Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru.

Authors:  M J Magee; E Bloss; S S Shin; C Contreras; H Arbanil Huaman; J Calderon Ticona; J Bayona; C Bonilla; M Yagui; O Jave; J P Cegielski
Journal:  Int J Infect Dis       Date:  2013-02-22       Impact factor: 3.623

2.  Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.

Authors:  Yong Chen; Zhengan Yuan; Xin Shen; Jie Wu; Zheyuan Wu; Biao Xu
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 3.  Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Authors:  William A Wells; Catharina C Boehme; Frank G J Cobelens; Colleen Daniels; David Dowdy; Elizabeth Gardiner; Jan Gheuens; Peter Kim; Michael E Kimerling; Barry Kreiswirth; Christian Lienhardt; Khisi Mdluli; Madhukar Pai; Mark D Perkins; Trevor Peter; Matteo Zignol; Alimuddin Zumla; Marco Schito
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

4.  Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.

Authors:  D M P Ramalho; P F C Miranda; M K Andrade; T Brígido; M P Dalcolmo; E Mesquita; C F Dias; A N Gambirasio; J Ueleres Braga; A Detjen; P P J Phillips; I Langley; P I Fujiwara; S B Squire; M M Oliveira; A L Kritski
Journal:  BMC Infect Dis       Date:  2017-08-15       Impact factor: 3.090

5.  Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study.

Authors:  Gustavo E Velásquez; J Peter Cegielski; Megan B Murray; Martin J A Yagui; Luis L Asencios; Jaime N Bayona; César A Bonilla; Hector O Jave; Gloria Yale; Carmen Z Suárez; Eduardo Sanchez; Christian Rojas; Sidney S Atwood; Carmen C Contreras; Janeth Santa Cruz; Sonya S Shin
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.